Salud financiera de hoja de balance de ArriVent BioPharma
Salud financiera controles de criterios 5/6
ArriVent BioPharma has a total shareholder equity of $296.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $308.9M and $12.2M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$298.67m |
| Patrimonio | US$296.66m |
| Total pasivo | US$12.20m |
| Activos totales | US$308.86m |
Actualizaciones recientes sobre salud financiera
Análisis de la situación financiera
Pasivos a corto plazo: AVBP's short term assets ($308.5M) exceed its short term liabilities ($12.1M).
Pasivo a largo plazo: AVBP's short term assets ($308.5M) exceed its long term liabilities ($98.0K).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AVBP is debt free.
Reducción de la deuda: AVBP had no debt 5 years ago.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: AVBP has sufficient cash runway for more than 3 years based on its current free cash flow.
Pronóstico de cash runway: Insufficient data to determine if AVBP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.